{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.4"},{"groupId":"OG001","value":"24.2"},{"groupId":"OG002","value":"5.9"}]}],"title":"Anemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.4"},{"groupId":"OG001","value":"12.1"},{"groupId":"OG002","value":"0"}]}],"title":"Febrile neutropenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.6"},{"groupId":"OG001","value":"1.21"},{"groupId":"OG002","value":"0"}]}],"title":"Fatigue"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"5.9"}]}],"title":"Flu-like symptoms"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.4"},{"groupId":"OG001","value":"9.1"},{"groupId":"OG002","value":"5.9"}]}],"title":"Lung infection"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"9.1"},{"groupId":"OG002","value":"0"}]}],"title":"Sepsis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"6.1"},{"groupId":"OG002","value":"0"}]}],"title":"Upper respiratory infection"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.4"},{"groupId":"OG001","value":"9.1"},{"groupId":"OG002","value":"11.8"}]}],"title":"Lymphodemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.4"},{"groupId":"OG001","value":"51.5"},{"groupId":"OG002","value":"23.5"}]}],"title":"Neutropenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7"},{"groupId":"OG001","value":"15.2"},{"groupId":"OG002","value":"0"}]}],"title":"Thrombocytopenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.3"},{"groupId":"OG001","value":"12.1"},{"groupId":"OG002","value":"5.9"}]}],"title":"Leukopenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"6.1"},{"groupId":"OG002","value":"0"}]}],"title":"Hyperglycemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"6.1"},{"groupId":"OG002","value":"0"}]}],"title":"Hyponatremia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"5.9"}]}],"title":"Hypophosphatemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"5.9"}]}],"title":"Hypoxia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"6.1"},{"groupId":"OG002","value":"0"}]}],"title":"Confusion"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"9.1"},{"groupId":"OG002","value":"0"}]}],"title":"Pneumonitis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"6.1"},{"groupId":"OG002","value":"0"}]}],"title":"Thromboembolic event"}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"33"},{"groupId":"OG002","value":"17"}],"units":"Participants"}],"description":"Phase II: Participants with Grade 3 or 4 adverse events at least possibly related to the study treatment in 5% of participants in the Phase 2 portion, by AE category, assessed by the National Cancer Institute Common Terminology Criteria (NCI CTC) version 4.0.","groups":[{"description":"Phase II: Pomalidomide and high dose dexamethasone.\n\nCrossover Arm D is a part of Arm B. Arm D was opened later to accommodate requested transfers from Arm B. Participants who experienced progressive disease in arm B were allowed to crossover to arm D at the discretion of the treating physician.\n\nArm D participants may be referenced separately in some Outcome Measures.","id":"OG000","title":"B: Pomalidomide and Dexamethasone"},{"description":"Phase II: Pomalidomide high dose dexamethasone and oral cyclophosphamide.","id":"OG001","title":"C: Pomalidomide, Dexamethasone, Cyclophosphamide"},{"description":"Phase II: Participants who crossed over from Arm B to Arm D. Crossover Arm D is a part of Arm B. Arm D was opened later to accommodate requested transfers from Arm B. Participants who experienced progressive disease in arm B were allowed to crossover to arm D at the discretion of the treating physician.","id":"OG002","title":"D: Crossover Arm"}],"paramType":"NUMBER","populationDescription":"All Phase II Participants who completed allocated intervention.","reportingStatus":"POSTED","timeFrame":"Up to 48 Months","title":"Phase II - Occurrence of Possibly Related Adverse Events (AEs)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}